Ki-67 Proliferation Index in Lymphoma: An Educational Review of a Prognostic Biomarker

Introduction

The Ki-67 proliferation index is among the most widely used ancillary tests in hematopathology. It is deceptively simple—a single immunohistochemical stain reported as a percentage—yet it carries meaningful prognostic weight in several lymphoid neoplasms and contributes to the distinction between aggressive and indolent disease. This article reviews what the marker measures, how it is assessed, and how pathologists interpret the result across different diagnostic contexts.

What the Test Measures

Ki-67 is a nuclear protein expressed by cells that have entered the active phases of the cell cycle (G1, S, G2, and mitosis) but is absent in resting cells (G0). Because of this cell-cycle–restricted expression, the proportion of tumor nuclei staining for Ki-67 serves as a direct morphometric estimate of the growth fraction of a neoplasm. In lymphomas, a higher fraction of proliferating cells generally reflects more aggressive biological behavior, while a lower fraction is characteristic of slower-growing, indolent processes.

It is important to frame Ki-67 as a measure of proliferative activity, not of lineage, clonality, or any specific genetic lesion. It complements—rather than replaces—morphology, immunophenotyping, and molecular studies in reaching a final diagnosis and prognostic assessment.

How It Is Tested

Ki-67 is evaluated by immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded (FFPE) tissue. The antibody most commonly employed recognizes the Ki-67 antigen, producing a nuclear staining pattern that is read by light microscopy.

Specimen and preanalytic constraints. Because the assay is performed on FFPE material, the quality of the result depends heavily on preanalytic handling. Adequate and prompt fixation, appropriate tissue thickness, and well-preserved nuclear morphology are all necessary for reliable staining. Poorly fixed, crushed, or necrotic areas can produce artifactual staining or loss of signal and should be avoided during scoring.

Scoring. The result is expressed as the percentage of tumor cell nuclei showing positive staining. In practice, scoring may be performed by visual estimation across representative fields, by counting cells in selected high-power fields, or with the assistance of digital image analysis. Attention should be directed to the neoplastic population, since admixed reactive cells—such as proliferating benign lymphocytes in germinal centers or histiocytes—can confound the estimate if not distinguished. Interobserver variability and choice of scoring method are recognized sources of variation, a point returned to below.

What Each Result State Means

The prognostic and diagnostic meaning of a Ki-67 index is entity-specific; the same numeric value can carry different significance depending on the lymphoma type.

• Low index. A low proliferation fraction is generally consistent with, and supportive of, indolent biology. In the appropriate morphologic and immunophenotypic context, it helps steer interpretation toward a more slowly progressive process.

• High index. A high proliferation fraction indicates a large growth fraction and, in many contexts, more aggressive behavior. In mantle cell lymphoma (MCL) specifically, the Ki-67 index is a key prognostic parameter. Data from the European Mantle Cell Lymphoma Network randomized trials established that a higher Ki-67 index is associated with inferior outcomes and that the index provides prognostic information independent of clinical scoring, supporting its incorporation into risk assessment [3]. Both the WHO 5th edition and the International Consensus Classification recognize proliferation as a clinically relevant biological variable in MCL [1,2].

• ~100% (Burkitt lymphoma). Burkitt lymphoma is characterized by an extremely high proliferation fraction, approaching or reaching essentially 100% of tumor nuclei. A near-100% index is one of the supporting features—alongside characteristic morphology, immunophenotype, and MYC rearrangement—used in recognizing Burkitt lymphoma [1,2]. It is essential to emphasize that a very high Ki-67 alone does not establish this diagnosis; it must be integrated with the full constellation of findings.

What It Determines for Treatment Eligibility

Ki-67 functions principally as a prognostic biomarker—it helps estimate the likely clinical course and stratify risk—rather than as a direct predictor of response to a specific agent.

In mantle cell lymphoma, the proliferation index contributes to prognostic grading that informs whether a patient's disease is likely to behave more or less aggressively; this in turn contributes to the framework within which clinicians consider eligibility for more or less intensive therapeutic approaches [3]. In the diagnostic separation of aggressive from indolent lymphomas, a near-100% index supporting a Burkitt diagnosis is relevant because Burkitt lymphoma is managed as an aggressive entity and the classification itself informs eligibility for aggressive chemotherapy regimen classes.

The essential educational point is that Ki-67 informs disease classification and risk category, which in turn shape eligibility for broad drug classes—not an individualized recommendation for any particular treatment. Therapeutic decisions rest with the treating clinical team and integrate many additional factors.

Caveats and What Is Evolving

Several limitations deserve emphasis. First, cutoffs remain contested and method-dependent. There is no single universally standardized threshold that cleanly separates prognostic categories across all entities and laboratories; the choice of scoring approach (visual estimation versus counting versus digital analysis) can shift results, and interobserver variability is well recognized. As with other quantitative IHC biomarkers where thresholds are actively debated, the field continues to work toward greater reproducibility and harmonization.

Second, Ki-67 must never be interpreted in isolation. Preanalytic factors, contaminating reactive proliferation, and tissue quality can all distort the result. The index is meaningful only in the context of morphology, immunophenotype, and molecular findings, and its prognostic interpretation is specific to the diagnosed entity [1,2,3].

Finally, the evidence supporting Ki-67's prognostic role is strongest in specific settings—most notably mantle cell lymphoma—and its use elsewhere should be understood as entity-specific and, in some contexts, still evolving.

References

1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the WHO Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022. doi:10.1038/s41375-022-01620-2

2. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms. Blood. 2022. doi:10.1182/blood.2022015851

3. Hoster E, et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. Journal of Clinical Oncology. 2016. PMID:26926679